SCHEMBL29925328

SCHEMBL29925328

O=C1COc2cccc(c2)-c2n[nH]c3ccc(cc23)OCCCN1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 3/20 0.44
DYRK1A Q13627 3/20 0.44
CLK2 P49760 2/20 0.44
CLK3 P49761 1/20 0.44
DCLK1 O15075 1/20 0.38
PRKD3 O94806 1/20 0.38
MAP4K4 O95819 1/20 0.38
CHEK2 O96017 1/20 0.38
CSF1R P07333 1/20 0.38
FER P16591 1/20 0.38
CDK2 P24941 1/20 0.38
MARK3 P27448 1/20 0.38
FLT4 P35916 1/20 0.38
FLT3 P36888 1/20 0.38
MAPK9 P45984 1/20 0.38
CSNK1D P48730 1/20 0.38
CSNK2A1 P68400 1/20 0.38
CSNK1G2 P78368 1/20 0.38
MAP4K2 Q12851 1/20 0.38
STK3 Q13188 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27032504 1.00 GSK3B (0.44) GSK3BDYRK1ACLK2CLK3DCLK1
SCHEMBL29925739 0.93 DYRK1A (0.45) GSK3BDYRK1ACLK2CLK3DCLK1
SCHEMBL27031760 0.87 DYRK1A (0.43) GSK3BDYRK1ACLK2CLK3DCLK1
SCHEMBL29925212 0.87 DYRK1A (0.43) GSK3BDYRK1ACLK2CLK3DCLK1
SCHEMBL27031905 0.86 DYRK1A (0.38) GSK3BDYRK1ACLK2CLK3DCLK1
SCHEMBL27031900 0.86 GSK3B (0.35) GSK3BDYRK1ACLK2CLK3DCLK1
SCHEMBL29925477 0.86 GSK3B (0.35) GSK3BDYRK1ACLK2CLK3DCLK1
SCHEMBL29925226 0.86 GSK3B (0.37) GSK3BDYRK1ACLK2CLK3DCLK1
SCHEMBL27031770 0.86 MAP2K4 (0.38) GSK3BDYRK1ACLK2CLK3DCLK1
SCHEMBL27031818 0.86 GSK3B (0.37) GSK3BDYRK1ACLK2CLK3DCLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240246992-A1 MACROCYCLIC LRRK2 KINASE INHIBITORS SERVIER LAB (FR) 2024-07-25 US claimed
EP-4308570-A1 MACROCYCLIC LRRK2 KINASE INHIBITORS Les Laboratoires Servier (FR) 2024-01-24 EP claimed
WO-2022194976-A1 MACROCYCLIC LRRK2 KINASE INHIBITORS LES LABORATOIRES SERVIER (FR) 2022-09-22 WO claimed
US-20240246992-A1 MACROCYCLIC LRRK2 KINASE INHIBITORS SERVIER LAB (FR) 2024-07-25 US disclosed
EP-4308570-A1 MACROCYCLIC LRRK2 KINASE INHIBITORS Les Laboratoires Servier (FR) 2024-01-24 EP disclosed
WO-2022194976-A1 MACROCYCLIC LRRK2 KINASE INHIBITORS LES LABORATOIRES SERVIER (FR) 2022-09-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240246992-A1 MACROCYCLIC LRRK2 KINASE INHIBITORS LRRK2, PARK7, PINK1 GSK3B 120/4885DYRK1A 993/4885CLK2 16/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.